Bill Grossman, Arcus Biosciences, Inc.'s Chief Medical Officer, Resigns
July 19, 2021 at 04:47 pm EDT
Share
On July 16, 2021, Bill Grossman, MD, Arcus Biosciences, Inc.'s Chief Medical Officer, resigned from Arcus to become SVP of Oncology Clinical Research at Gilead Sciences, Inc., effective July 26, 2021. Arcus and Dr. Grossman subsequently entered into a separation agreement pursuant to which he will (a) provide consulting services to Arcus for a period of up to 3 months and (b) receive an extension of his stock option exercise period to July 1, 2022.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.